Transforming vaccines with breakthrough VLP technology

Corporate profile

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and its pipeline includes additional programs in influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.

Press releases

May 22, 2023
Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock
May 22, 2023
Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
May 10, 2023
Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update


May 22, 2023 at 6:00 PM EDT
Icosavax Investor Call
March 13, 2023 at 12:40 PM EDT
Oppenheimer 33rd Annual Healthcare Conference
March 7, 2023 at 9:10 AM EST
Cowen 43rd Annual Health Care Conference

Latest presentation

May 2023
IVX A12 Phase 1 Topline Data
Investor Email Alerts